Avadel Pharmaceuticals plc (AVDL) 是一家上市公司 属于 医疗保健 板块，经营于 制药 - 专科与仿制药 行业. 公司总部位于 Dublin, 爱尔兰. 现任CEO为 Gregory J. Divis Jr..
AVDL 拥有 IPO日期为 1996-06-07, 188 名全职员工, 在 NASDAQ Global Market, 市值为 $2.12B.
Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is FT218, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.
